Ireland
--:--IST
Enrolling by invitation Not applicable

Development of Anti-Diabetic Nutraceuticals From Legume Seed Coats

NCT07688694 · tracked via the Priya Life Science India tracker
Sponsor
JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH
Phase
Not applicable
Started
2026-06-22
Last updated
2026-07-07

Condition(s) studied

Postprandial HyperglycemiaType 2 DiabetesMetabolic Syndromes

Investigational drug(s) / intervention(s)

Legumes seed soup

Legumes seed soup: The pre-processed seed coats of legumes (Vigna mungo or Macrotyloma uniflorum) are boiled to obtain extracts, combined with varying amounts of cooked cotyledons, and seasoned with salt and spices.

Study summary

This open-label clinical trial aims to evaluate whether daily consumption of soup prepared from boiled water extracts of selected legume seed coats, seasoned with salt and spices, improves glycemic regulation in individuals with metabolic syndrome or type 2 diabetes mellitus (T2DM). The primary question is whether daily intake of this palatable legume-based soup enhances glycemic control. Secondary questions include whether it reduces dyslipidemia, oxidative stress, and inflammation in participants with metabolic syndrome or T2DM. Participants will consume the soup once daily for 30 consecutive days. Clinical assessments, including HbA1c, fasting blood glucose, lipid profile, and biomarkers of oxidative stress and inflammation will be conducted at baseline and after the 30-day intervention.

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: i. Healthy volunteers aged 20 to \<60 years. ii. Individuals with one or more of the following risk factors: BMI \>25 kg/m², systolic blood pressure (SBP) \>130 mmHg, dyslipidemia, or HbA1c between 5.7-6.4% (prediabetes range). iii. Adults diagnosed with type 2 diabetes mellitus (T2DM). Exclusion Criteria: i. History of gastrointestinal diseases. ii. Use of antibiotics within the past 3 months. iii. Pregnant or lactating women. iv. Individuals diagnosed with cardiovascular disease, chronic kidney disease, cancer, liver disease, or autoimmune disorders. v. Current use of alpha-glucosidase inhibitor medications.

Primary outcome measure(s)

  • Change from baseline in Fasting blood glucose and HbA1c at 4 weeks — Baseline and 4th week
    Fasting blood glucose and plasma HbA1c measured at clinical biochemistry diagnostic laboratory.
  • Change from baseline in capillary blood glucose levels after meal at 2 and 4 week — Baseline, 2nd week and 4th week
    Capillary blood glucose levels at baseline, 30 min, 60 min, 90 min and 120 min after a meal by glucometer

Trial sites (1)

FacilityCityRegionStatus
JSS Medical College Mysore Karnataka

More JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07688694 on ClinicalTrials.gov ↗ ← All trials in India